{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:11Z","timestamp":1787009951469,"version":"build-2736575974"},"reference-count":110,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:p>Analgesic medications compounded for topical use are gaining popularity for the management of chronic pain. The advantages of topical pain medications include reduction of systemic adverse effects, improved patient acceptance, few drug interactions, ease of dose determination, avoidance of first-pass metabolism, and direct access to the target site. Compounded topical medications typically use a mixture of 3 or more single medications to achieve multiple complementary effects at lower doses of each individual medication. Herein, we review the mechanisms, adverse effects, and evidence for some of the most commonly used medications in topical compounds for pain management. Because more topical medications are used for chronic pain, dermatologists can expect an increase in irritant and allergic contact dermatitis related to these medications.<\/jats:p>","DOI":"10.1097\/der.0000000000000216","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T07:12:50Z","timestamp":1474355570000},"page":"263-271","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Compounded Topical Analgesics for Chronic Pain"],"prefix":"10.1177","volume":"27","author":[{"given":"Abigail E.","family":"Cline","sequence":"first","affiliation":[{"name":"From the, *Medical College of Georgia, Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake E.","family":"Turrentine","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.009"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","DOI":"10.1002\/9780470522226","volume-title":"Peripheral Receptor Targets for Analgesia: Novel Approaches to Pain Management","author":"Cairns BE","year":"2009","unstructured":"Cairns BE. Peripheral Receptor Targets for Analgesia: Novel Approaches to Pain Management. New Jersey, NJ: Wiley; 2009."},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.11.015"},{"issue":"1","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/AJP.0b013e318285d1ba","article-title":"Topical treatment of neuropathic pain using compounded medications","volume":"30","author":"Zur E","year":"2014","unstructured":"Zur E. Topical treatment of neuropathic pain using compounded medications. Clin J Pain, 2014; 30(1):73\u201391.","journal-title":"Clin J Pain"},{"issue":"10","key":"e_1_3_1_6_2","first-page":"7","article-title":"Topical analgesics in treating neuropathic and musculoskeletal pain","volume":"11","author":"Zempsky W","year":"2013","unstructured":"Zempsky W. Topical analgesics in treating neuropathic and musculoskeletal pain. Pain Medicine News, 2013; 11(10):7\u201310.","journal-title":"Pain Medicine News"},{"issue":"1","key":"e_1_3_1_7_2","first-page":"6","article-title":"Chronic neuropathic pain: pharmacological interventions in the new millennium","volume":"4","author":"Jones M","year":"2000","unstructured":"Jones M. Chronic neuropathic pain: pharmacological interventions in the new millennium. Int J Pharm Compd, 2000; 4(1):6\u201315.","journal-title":"Int J Pharm Compd"},{"issue":"3","key":"e_1_3_1_8_2","first-page":"182","article-title":"A brief survey on prescriber beliefs regarding compounded topical pain medications","volume":"18","author":"Warner M","year":"2014","unstructured":"Warner M, , Tuder D. A brief survey on prescriber beliefs regarding compounded topical pain medications. Int J Pharm Compd, 2014; 18(3):182\u2013188.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_1_9_2","unstructured":"Bennett A. Topical prescription creams reduce pain in five of every six chronic pain patients without need for opioids or other narcotics. Patient Outcomes Analytics; 2013. Available at: http:\/\/globenewswire.com\/. Accessed January19 2016."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200507000-00021"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.7547\/1020178"},{"issue":"3","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1590\/S0365-05962012000300032","article-title":"Topical (S)-ketamine for pain management of postherpetic neuralgia","volume":"87","author":"Barros GA","year":"2012","unstructured":"Barros GA, , Miot HA, , Braz AM, et al. Topical (S)-ketamine for pain management of postherpetic neuralgia. An Bras Dermatol, 2012; 87(3):504\u2013505.","journal-title":"An Bras Dermatol"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181827c77"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.04.014"},{"issue":"4","key":"e_1_3_1_15_2","first-page":"346","article-title":"Topical clonidine for orofacial pain: a pilot study","volume":"11","author":"Epstein JB","year":"1997","unstructured":"Epstein JB, , Grushka M, , Le N. Topical clonidine for orofacial pain: a pilot study. J Orofac Pain, 1997; 11(4):346\u2013352.","journal-title":"J Orofac Pain"},{"key":"e_1_3_1_16_2","first-page":"Cd010967","article-title":"Topical clonidine for neuropathic pain","volume":"8","author":"Wrzosek A","year":"2015","unstructured":"Wrzosek A, , Woron J, , Dobrogowski J, et al. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev, 2015; 8:Cd010967.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318156db26"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200929060-00003"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200009000-00005"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00317-8"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38042.506748.EE"},{"issue":"5","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/j.1532-2149.2013.00415.x","article-title":"Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study","volume":"18","author":"Maihofner CG","year":"2014","unstructured":"Maihofner CG, , Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Eur J Pain, 2014; 18(5):671\u2013679.","journal-title":"Eur J Pain"},{"issue":"10","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00296-012-2490-5","article-title":"Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients","volume":"33","author":"Casanueva B","year":"2013","unstructured":"Casanueva B, , Rodero B, , Quintial C, et al. Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatol Int, 2013; 33(10):2665\u201370. doi: 10.1007\/s00296-012-2490-5.","journal-title":"Rheumatol Int"},{"issue":"3","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0976-3147.118766","article-title":"Sensory profile and its impact on quality of life in patients with painful diabetic polyneuropathy","volume":"4","author":"Kulkantrakorn K","year":"2013","unstructured":"Kulkantrakorn K, , Lorsuwansiri C. Sensory profile and its impact on quality of life in patients with painful diabetic polyneuropathy. J Neurosci Rural Pract, 2013; 4(3):267\u2013270.","journal-title":"J Neurosci Rural Pract"},{"key":"e_1_3_1_25_2","first-page":"CD007402","article-title":"Topical NSAIDs for acute musculoskeletal pain in adults","volume":"6","author":"Derry S","year":"2015","unstructured":"Derry S, , Moore RA, , Gaskell H, et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev, 2015; 6:CD007402.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/pme.12611","article-title":"Comparison of NSAID patch given as monotherapy and NSAID patch in combination with transcutaneous electric nerve stimulation, a heating pad, or topical capsaicin in the treatment of patients with myofascial pain syndrome of the upper trapezius: a pilot study","volume":"15","author":"Kim DH","year":"2014","unstructured":"Kim DH, , Yoon KB, , Park S, et al. Comparison of NSAID patch given as monotherapy and NSAID patch in combination with transcutaneous electric nerve stimulation, a heating pad, or topical capsaicin in the treatment of patients with myofascial pain syndrome of the upper trapezius: a pilot study. Pain Med, 2014; 15(12):2128\u20132138.","journal-title":"Pain Med"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000693"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2158-7"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0911-0"},{"issue":"3","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jpain.2004.02.294","article-title":"Topical analgesics","volume":"5","author":"Lockhart E","year":"2014","unstructured":"Lockhart E. Topical analgesics. J Pain, 2014; 5(3):S82.","journal-title":"J Pain"},{"issue":"4","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","DOI":"10.1097\/LGT.0b013e31819663ee","article-title":"Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia","volume":"13","author":"Nyirjesy P","year":"2009","unstructured":"Nyirjesy P, , Lev-Sagie A, , Mathew L, et al. Topical amitriptyline-baclofen cream for the treatment of provoked vestibulodynia. J Low Genit Tract Dis, 2009; 13(4).","journal-title":"J Low Genit Tract Dis"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(97)00010-6"},{"issue":"2","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(00)00944-7","article-title":"Localization of ionotropic glutamate receptors in peripheral axons of human skin","volume":"283","author":"Kinkelin I","year":"2000","unstructured":"Kinkelin I, , Brocker EB, , Koltzenburg M, et al. Localization of ionotropic glutamate receptors in peripheral axons of human skin. Neurosci Lett, 2000; 283(2):149\u2013152.","journal-title":"Neurosci Lett"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(98)01328-6"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1983.tb11031.x"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01116-3"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)90149-X"},{"issue":"1","key":"e_1_3_1_38_2","first-page":"63","article-title":"The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study","volume":"81","author":"Arendt-Nielsen L","year":"1995","unstructured":"Arendt-Nielsen L, , Petersen-Felix S, , Fischer M, et al. The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth Analg, 1995; 81(1):63\u201368.","journal-title":"Anesth Analg"},{"issue":"8","key":"e_1_3_1_39_2","first-page":"805","article-title":"and oral ketamine","volume":"53","author":"Grant IS","year":"1981","unstructured":"Grant IS, , Nimmo WS, , Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth, 1981; 53(8):805\u2013810.","journal-title":"Br J Anaesth"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)90129-5"},{"issue":"7","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/0885-3924(95)00102-5","article-title":"Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain","volume":"10","author":"Mercadante S","year":"1995","unstructured":"Mercadante S, , Lodi F, , Sapio M, et al. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage, 1995; 10(7):564\u2013568.","journal-title":"J Pain Symptom Manage"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96574910.x"},{"issue":"3","key":"e_1_3_1_43_2","first-page":"27","article-title":"Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration","volume":"16","author":"Kronenberg RH","year":"2002","unstructured":"Kronenberg RH. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother, 2002; 16(3):27\u201335.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4637.2000.00006.x"},{"issue":"2","key":"e_1_3_1_45_2","first-page":"122","article-title":"Clinical application of ketamine ointment in the treatment of sympathetically maintained pain","volume":"2","author":"Crowley KL","year":"1998","unstructured":"Crowley KL, , Flores JA, , Hughes CN, et al. Clinical application of ketamine ointment in the treatment of sympathetically maintained pain. Int J Pharm Compd, 1998; 2(2):122\u2013127.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.05.017"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055848.00032.39"},{"issue":"1","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.ajp.0000149800.39240.95","article-title":"Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia","volume":"22","author":"Poyhia R","year":"2006","unstructured":"Poyhia R, , Vainio A. Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia. Clin J Pain, 2006; 22(1):32\u201336.","journal-title":"Clin J Pain"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.01.001"},{"key":"e_1_3_1_50_2","first-page":"S269","article-title":"New and emerging treatment options for neuropathic pain","volume":"12","author":"Gidal BE","year":"2006","unstructured":"Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care, 2006; 12(9 suppl):S269\u2013S278.","journal-title":"Am J Manag Care"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5768"},{"issue":"3","key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0304-3959(99)00283-3","article-title":"Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn","volume":"85","author":"Shimoyama M","year":"2000","unstructured":"Shimoyama M, , Shimoyama N, , Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain, 2000; 85(3):405\u2013414.","journal-title":"Pain"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00154-2"},{"issue":"3","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0022-3565(24)38054-1","article-title":"Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats","volume":"288","author":"Pan HL","year":"1999","unstructured":"Pan HL, , Eisenach JC, , Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther, 1999; 288(3):1026\u20131030.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00018-003-2108-x","article-title":"Cellular and molecular action of the putative GABA-mimetic, gabapentin","volume":"60","author":"Maneuf YP","year":"2003","unstructured":"Maneuf YP, , Gonzalez MI, , Sutton KS, et al. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci, 2003; 60(4):742\u2013750.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"e_1_3_1_56_2","first-page":"1062","article-title":"Gabapentin: an update of its pharmacological properties and therapeutic use in epilepsy","volume":"16","author":"Honarmand A","year":"2011","unstructured":"Honarmand A, , Safavi M, , Zare M. Gabapentin: an update of its pharmacological properties and therapeutic use in epilepsy. J Res Med Sci, 2011; 16(8):1062\u20131069.","journal-title":"J Res Med Sci"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P777"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006119.x"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X1003800306"},{"issue":"4","key":"e_1_3_1_60_2","first-page":"280","article-title":"Gabapentin vs","volume":"20","author":"Dallocchio C","year":"2000","unstructured":"Dallocchio C, , Buffa C, , Mazzarello P, et al. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage, 2000; 20(4):280\u2013285.","journal-title":"amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage"},{"issue":"9","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1399-6576.2004.00484.x","article-title":"\u2018Protective premedication\u2019: an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain","volume":"48","author":"Dahl JB","year":"2004","unstructured":"Dahl JB, , Mathiesen O, , Moiniche S. \u2018Protective premedication\u2019: an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiol Scand, 2004; 48(9):1130\u20131136.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"1","key":"e_1_3_1_62_2","first-page":"73","article-title":"Gabapentin to treat sacral perineural cyst-induced pain","volume":"54","author":"Magalhaes E","year":"2004","unstructured":"Magalhaes E, , Mascarenhas AM, , Kraychete DC, et al. Gabapentin to treat sacral perineural cyst-induced pain. Case report. Rev Bras Anestesiol, 2004; 54(1):73\u201377.","journal-title":"Case report. Rev Bras Anestesiol"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.21982"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200210000-00033"},{"issue":"2","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1526-4637.2002.02014.x","article-title":"Intrathecal clonidine in the treatment of intractable pain: a phase I\/II study","volume":"3","author":"Hassenbusch SJ","year":"2002","unstructured":"Hassenbusch SJ, , Gunes S, , Wachsman S, et al. Intrathecal clonidine in the treatment of intractable pain: a phase I\/II study. Pain Med, 2002; 3(2):85\u201391.","journal-title":"Pain Med"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15707.x"},{"issue":"3","key":"e_1_3_1_67_2","first-page":"391","article-title":"Epidural clonidine analgesia for intractable cancer pain","volume":"61","author":"Eisenach JC","year":"1995","unstructured":"Eisenach JC, , DuPen S, , Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain, 1995; 61(3):391\u2013399.","journal-title":"The Epidural Clonidine Study Group. Pain"},{"issue":"1","key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00045391-199901000-00004","article-title":"Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics","volume":"6","author":"Dias VC","year":"1999","unstructured":"Dias VC, , Tendler B, , Oparil S, et al. Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. Am J Ther, 1999; 6(1):19\u201324.","journal-title":"Am J Ther"},{"issue":"5","key":"e_1_3_1_69_2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1213\/01.ANE.0000083526.08033.20","article-title":"Intrathecal clonidine and severe hypotension after cardiopulmonary bypass","volume":"97","author":"Puskas F","year":"2003","unstructured":"Puskas F, , Carnporesi EM, , O\u2019Leary CE, et al. Intrathecal clonidine and severe hypotension after cardiopulmonary bypass. Anesth Analg, 2003; 97(5):1251\u20131253.","journal-title":"Anesth Analg"},{"issue":"2","key":"e_1_3_1_70_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00000542-200602000-00022","article-title":"Perineural clonidine reduces mechanical hypersensitivity and cytokine production in established nerve injury","volume":"104","author":"Romero-Sandoval A","year":"2006","unstructured":"Romero-Sandoval A, , Eisenach JC. Perineural clonidine reduces mechanical hypersensitivity and cytokine production in established nerve injury. Anesthesiology, 2006; 104(2):351\u2013355.","journal-title":"Anesthesiology"},{"issue":"3","key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0304-3959(91)90221-I","article-title":"Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain","volume":"47","author":"Davis KD","year":"1991","unstructured":"Davis KD, , Treede RD, , Raja SN, et al. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain, 1991; 47(3):309\u2013317.","journal-title":"Pain"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)00121-T"},{"issue":"1","key":"e_1_3_1_73_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0536.1987.tb02607.x","article-title":"Oral substitution in patients sensitized by transdermal clonidine treatment","volume":"16","author":"Maibach HI","year":"1987","unstructured":"Maibach HI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis, 1987; 16(1):1\u20138.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"e_1_3_1_74_2","first-page":"154","article-title":"Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides","volume":"63","author":"Polster AM","year":"1999","unstructured":"Polster AM, , Warner MR, , Camisa C. Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides. Cutis, 1999; 63(3):154\u2013155.","journal-title":"Cutis"},{"issue":"2","key":"e_1_3_1_75_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1524-6175.2001.00954.x","article-title":"Transdermal clonidine skin reactions","volume":"4","author":"Prisant LM","year":"2002","unstructured":"Prisant LM. Transdermal clonidine skin reactions. J Clin Hypertens (Greenwich), 2002; 4(2):136\u2013138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.3.283"},{"issue":"2","key":"e_1_3_1_77_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1533-2500.2011.00477.x","article-title":"High doses of topical amitriptyline in neuropathic pain: 2 cases and literature review","volume":"12","author":"Kopsky DJ","year":"2012","unstructured":"Kopsky DJ, , Hesselink JM. High doses of topical amitriptyline in neuropathic pain: 2 cases and literature review. Pain Pract, 2012; 12(2):148\u2013153.","journal-title":"Pain Pract"},{"issue":"9","key":"e_1_3_1_78_2","first-page":"887","article-title":"Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia","volume":"7","author":"Lehman JS","year":"2008","unstructured":"Lehman JS, , Sciallis GF. Effective use of topical amitriptyline hydrochloride 2.5% and ketamine hydrochloride 0.5% for analgesia in refractory proctodynia. J Drugs Dermatol, 2008; 7(9):887\u2013889.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2011.01.003","article-title":"Topical amitriptyline in post-traumatic neuropathic pain","volume":"41","author":"Liebregts R","year":"2011","unstructured":"Liebregts R, , Kopsky DJ, , Hesselink JM. Topical amitriptyline in post-traumatic neuropathic pain. J Pain Symptom Manage, 2011; 41:e6\u2013e7.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"e_1_3_1_80_2","first-page":"289","article-title":"Topical amitriptyline in healthy volunteers","volume":"28","author":"Gerner P","year":"2003","unstructured":"Gerner P, , Kao G, , Srinivasa V, et al. Topical amitriptyline in healthy volunteers. Reg Anesth Pain Med, 2003; 28(4):289\u2013293.","journal-title":"Reg Anesth Pain Med"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(94)90149-X"},{"issue":"6","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.bjp.0706898","article-title":"Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels","volume":"149","author":"Reis GM","year":"2006","unstructured":"Reis GM, , Duarte ID. Baclofen, an agonist at peripheral GABAB receptors, induces antinociception via activation of TEA-sensitive potassium channels. Br J Pharmacol, 2006; 149(6):733\u2013739.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"e_1_3_1_83_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.41.2.104","article-title":"Antidepressant treatment of fibromyalgia","volume":"41","author":"Arnold LM","year":"2000","unstructured":"Arnold LM, , Keck PEJr, , Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics, 2000; 41(2):104\u2013113.","journal-title":"A meta-analysis and review. Psychosomatics"},{"issue":"2","key":"e_1_3_1_84_2","first-page":"161","article-title":"Skin permeation and antinociception of compounded topical cyclobenzaprine hydrochloride formulations","volume":"19","author":"Bryson E","year":"2015","unstructured":"Bryson E, , Hartman R, , Arnold J, et al. Skin permeation and antinociception of compounded topical cyclobenzaprine hydrochloride formulations. Int J Pharm Compd, 2015; 19(2):161\u2013166.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000099"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A185"},{"key":"e_1_3_1_87_2","first-page":"Cd010958","article-title":"Topical lidocaine for neuropathic pain in adults","volume":"7","author":"Derry S","year":"2014","unstructured":"Derry S, , Wiffen PJ, , Moore RA, et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev, 2014; 7:Cd010958.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01433.x"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X12960"},{"issue":"2","key":"e_1_3_1_90_2","first-page":"172","article-title":"24-Hour application of the lidocaine patch 5% for 3 consecutive days is safe and well tolerated in healthy adult men and women","volume":"3","author":"Gammaitoni AR","year":"2002","unstructured":"Gammaitoni AR, , Alvarez NA. 24-Hour application of the lidocaine patch 5% for 3 consecutive days is safe and well tolerated in healthy adult men and women. Pain Med, 2002; 3(2):172.","journal-title":"Pain Med"},{"key":"e_1_3_1_91_2","unstructured":"Ukens C. Coed death tied to compounded drug. 2005: Drug Topics."},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000190"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0b013e3182819c51"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2007.06072"},{"issue":"7264","key":"e_1_3_1_95_2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/bmj.321.7264.778","article-title":"The management of post-herpetic neuralgia","volume":"321","author":"Cunningham AL","year":"2000","unstructured":"Cunningham AL, , Dworkin RH. The management of post-herpetic neuralgia. BMJ, 2000; 321(7264):778\u2013779.","journal-title":"BMJ"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318158ed9e"},{"key":"e_1_3_1_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2013.00400.x"},{"issue":"8","key":"e_1_3_1_98_2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/BF00314653","article-title":"Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course","volume":"238","author":"Peikert A","year":"1991","unstructured":"Peikert A, , Hentrich M, , Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol, 1991; 238(8):452\u2013456.","journal-title":"J Neurol"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00007-X"},{"key":"e_1_3_1_100_2","first-page":"Cd010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","volume":"9","author":"Derry S","year":"2012","unstructured":"Derry S, , Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev, 2012; 9:Cd010111.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"e_1_3_1_101_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/00003495-200060030-00004","article-title":"Oral versus topical NSAIDs in rheumatic diseases: a comparison","volume":"60","author":"Heyneman CA","year":"2000","unstructured":"Heyneman CA, , Lawless-Liday C, , Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs, 2000; 60(3):555\u2013574.","journal-title":"Drugs"},{"key":"e_1_3_1_102_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38159.639028.7C"},{"key":"e_1_3_1_103_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-5-28"},{"issue":"6","key":"e_1_3_1_104_2","first-page":"Cd007402","article-title":"Topical NSAIDs for acute pain in adults","author":"Massey T","year":"2010","unstructured":"Massey T, , Derry S, , Moore RA, et al. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev, 2010;(6):Cd007402.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"e_1_3_1_105_2","first-page":"101","article-title":"Pluronic lecithin organogel for local delivery of anti-inflammatory drugs","volume":"8","author":"Franckum J","year":"2004","unstructured":"Franckum J, , Ramsay D, , Das NG, et al. Pluronic lecithin organogel for local delivery of anti-inflammatory drugs. Int J Pharm Compd, 2004; 8(2):101\u2013105.","journal-title":"Int J Pharm Compd"},{"issue":"1","key":"e_1_3_1_106_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187221110789957228","article-title":"Drug delivery systems for local anesthetics","volume":"4","author":"de Paula E","year":"2010","unstructured":"de Paula E, , Cereda CM, , Tofoli GR, et al. Drug delivery systems for local anesthetics. Recent Pat Drug Deliv Formul, 2010; 4(1):23\u201334.","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"e_1_3_1_107_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19170"},{"key":"e_1_3_1_108_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006204"},{"key":"e_1_3_1_109_2","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S9492"},{"key":"e_1_3_1_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.11.004"},{"issue":"3","key":"e_1_3_1_111_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin RH","year":"2010","unstructured":"Dworkin RH, , O\u2019Connor AB, , Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc, 2010; 85(suppl 3):S3\u2013S14.","journal-title":"Mayo Clin Proc"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0000000000000216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:03:52Z","timestamp":1777399432000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10,1]]}},"alternative-id":["10.1097\/DER.0000000000000216"],"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000216","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}